The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers—and for children.
http://ift.tt/2plLzds
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου